Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug
Portfolio Pulse from Vandana Singh
Silo Pharma Inc (NASDAQ:SILO) has entered into a Device and CMC Development Master Plan with Resyca BV for its intranasal PTSD drug, SPC-15. This partnership aims to enhance the drug's delivery method, potentially increasing its efficacy and safety. The news has caused SILO's stock to surge by 63.1%, with a significant increase in trading volume.
July 18, 2024 | 4:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma's stock surged by 63.1% following the announcement of a partnership with Resyca BV to develop an intranasal PTSD drug. The partnership aims to enhance the drug's delivery method, potentially increasing its efficacy and safety.
The partnership with Resyca BV is a significant development for Silo Pharma, as it aims to enhance the delivery method of its lead candidate SPC-15, potentially increasing its efficacy and safety. This positive news has led to a substantial increase in SILO's stock price and trading volume.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100